International Journal for Innovative Engineering and Management Research
PEER REVIEWED OPEN ACCESS INTERNATIONAL JOURNAL
www.ijiemr.org

# IMPACT OF DGATI-INHIBITING AND ANTICANCER-BASED COMPOUNDS

**TUPE AVINASH PRABHAKAR , DR. ATUL ARJUN BARAVKAR**

DESIGNATION- RESEARCH SCHOLAR SUNRISE UNIVERSITY ALWAR RAJASTHAN
DESIGNATION- PROFESSOR SUNRISE UNIVERSITY ALWAR RAJASTHAN

## ABSTRACT

In addition, the study explores the impacts on the biological system and the pharmacokinetics and pharmaco dynamics of the synthetic chemicals, shedding light on their processing within the body. Dosage regimes and treatment results optimization depend on this detailed knowledge. The study fully embraces the intricacy of cancer biology by taking tumor heterogeneity and cancer development dynamics into account. Crucial to the bio-assessment is the compounds' path through clinical trials, which the study describes in great detail, beginning with Phase I trials that determine the maximum tolerated dose and continuing through Phase II trials that evaluate efficacy and large-scale Phase III trials that confirm therapeutic benefits. To guarantee safety, effectiveness, and quality, regulatory authorities use rigorous inspection, which is highlighted by a critical examination of the regulatory approval process. The bio-assessment technique includes post-marketing surveillance to track the effects of the compounds throughout time and find any unintended side effects. This study highlights the need of keeping up with the ever-changing field of cancer biology and always improving our therapeutic approaches.

**KEYWORDS:** DGATI-Inhibiting, Anticancer-Based Compounds, pharmaco dynamics, biological system, harmacokinetics, therapeutic approaches

## INTRODUCTION

In addition, a thorough comprehension of the molecular pathways is necessary for the bio-assessment of anticancer and DGAT1-inhibiting drugs. Accurate mechanistic investigations, such as target engagement tests, pathway analysis, and the clarification of the compounds' action mechanism, play a crucial role in confirming these compounds as possible therapeutic agents. We can improve synthetic processes and optimize chemical design to increase efficacy and decrease risk of side effects by critically examining these mechanistic

discoveries. An interdisciplinary strategy is necessary for the critical investigation of DGAT1-inhibiting and anticancer-based drug synthesis and bio-assessment. The area is complicated and dynamic. While bio-assessment necessitates a thorough examination of pharmacological profiles and mechanistic insights, synthesis methods necessitate meticulous consideration of the structure-activity connection, scalability, and efficiency. This comprehensive study is crucial for improving our knowledge of these chemicals, overcoming obstacles in drug development, and finding new and effective treatments for cancer and lipid metabolism.

**DGATI-INHIBITING**

An enzyme known as DGAT1 (diacylglycerol O-acyltransferase 1) is essential for lipid metabolism and the production of triglycerides in particular. The body's ability to store and transfer energy relies on triglycerides, a specific kind of fat. The addition of an acyl group to diacylglycerol is the last step in triglyceride synthesis, and this reaction is catalyzed by DGAT1. Overconsumption of triglycerides, despite their need for maintaining an equilibrium of energy levels, can lead to insulin resistance and obesity, among other metabolic diseases. To modify lipid metabolism and treat related metabolic diseases, scientists have recently concentrated on creating DGAT1 inhibitors.

Chemicals that can selectively and efficiently block the activity of DGAT1 are designed and developed during the production of these inhibitors. These inhibitors may help in the management of disorders linked to aberrant lipid metabolism by modifying lipid levels, especially triglycerides. Investigating DGAT1 inhibitors involves both medicinal chemistry (the study of designing and synthesizing compounds) and bio-assessment (the study of carefully evaluating their effects on biological systems).

Optimizing the efficacy, selectivity, and pharmacokinetic features of DGAT1 inhibitors is an ongoing goal in medicinal chemistry. In order to improve the inhibitory effect of drugs against DGAT1, structure-activity relationship (SAR) investigations direct the change of chemical structures. In order to produce inhibitors, rational drug design methods use information about the DGAT1 enzyme's three-dimensional structure to find important binding sites and interactions. In order to investigate the SAR and find promising prospects

for future development, a library of compounds with different structures is being generated by the synthesis of various chemical entities, such as small molecules and peptidomimetics.

Evaluation of DGAT1 inhibitors' effects on lipid metabolism-related cellular and physiological processes is an integral part of their bio-assessment. Research on the effects of DGAT1 inhibitors on lipid production, storage, and secretion can be done in vitro using cell culture models. The effectiveness of inhibitors in regulating cellular lipid metabolism can be quantitatively determined by tests assessing triglyceride levels, lipid droplet formation, and intracellular lipid content. Additionally, selectivity against other lipid synthesis enzymes and possible off-target effects are both included in the bio-assessment.

Evaluating the safety and effectiveness of DGAT1 inhibitors in a physiological setting relies heavily on in vivo studies, which are frequently carried out using animal models. To determine how inhibitors affect lipid profiles, body weight, and glucose homeostasis, researchers frequently use rodents like rats and mice. Researchers in these investigations track a number of metabolic markers in animals after they've been given DGAT1 inhibitors. The effects of DGAT1 inhibition on lipid distribution and accumulation can be better understood by histological examinations of several tissues, including adipose tissue and the liver. To further understand the metabolic effects of DGAT1 inhibitors, it is helpful to conduct metabolic evaluations such as glucose tolerance tests and insulin sensitivity studies.

**ANTICANCER-BASED COMPOUNDS**

Combating cancer, a complex and multidimensional group of disorders characterized by uncontrolled cell growth and proliferation, is the principal goal of anticancer-based drugs, a diverse and dynamic class of chemicals. The diverse chemical structures and action mechanisms of these substances highlight the complexity of cancer biology and the requirement for flexible and tailored treatment methods. Research into the bio-assessment, synthesis, and identification of anticancer-based substances is a thriving field that aspires to improve cancer treatment, patient outcomes, and molecular understanding of the disease.

Making chemical entities with the intent of interfering with particular targets or pathways vital to the proliferation and survival of cancer cells is the goal of anticancer drug synthesis. To create a wide range of compounds with possible anticancer effects, medicinal chemists

use a wide range of synthetic techniques. In order to maximize the specificity and effectiveness of anticancer drugs, the synthetic process incorporates rational drug design, structure-activity relationship (SAR) investigations, and high-throughput screening. A multifaceted strategy is required to address the heterogeneity of cancer, and the chemical diversity of these chemicals reflects that. They include small molecules, peptides, antibodies, and nucleic acid-based therapies.

A large class of anticancer drugs, small molecules are defined by their affinity for particular cell types and their relatively modest molecular weight. It is common practice to either alter preexisting chemical scaffolds or create completely new structures while synthesizing small molecule anticancer medicines. Alkylating agents, antimetabolites, and topoisomerase inhibitors are chemotherapeutic drugs that kill cancer cells by interfering with their ability to replicate and repair DNA. Aiming for a moderate level of cytotoxicity against cancer cells while keeping normal tissues safe is the goal of synthesising these tiny compounds.

Anticancer drugs based on peptides target cancer cells selectively or interfere with particular signaling pathways by taking use of the special characteristics of peptides. It is possible to improve the stability and binding affinity of peptides by adding modifications during solid-phase peptide synthesis. Anticancer peptide medications come in a variety of forms; some aim to replicate naturally occurring peptides that regulate cells, while others are developed to specifically target cancer cell surface receptors or proteins that are overexpressed. These chemicals show potential in precision medicine since they can be used to create targeted therapies that are based on the molecular features of certain cancers.

The immune system's capacity to identify and destroy foreign invaders, such as cancer cells, relies heavily on a family of big, complicated molecules called antibodies, or immunoglobulins. The development of monoclonal antibodies that can specifically target antigens found on cancer cell surfaces has brought about a dramatic shift in cancer treatment. Therapeutic antibodies are manufactured by creating these molecules using hybridoma cell lines or recombinant DNA technologies. An advanced method is the use of antibody-drug conjugates (ADCs), which link cytotoxic medicines to antibodies. This allows for the targeted delivery of toxic payloads to cancer cells while normal tissues are minimized.

Anticancer drugs based on nucleic acids include a wide variety of treatments that target cancer cells' DNA. Gene treatments, small interfering RNA (siRNA), and antisense oligonucleotides are all examples of what is grouped here. Generating nucleic acid-based medicines requires the development of sequences with the ability to influence the expression of cancer-related genes in a targeted manner. Possible effects of these chemicals include inducing cell death, enhancing the immune system's capacity to identify and destroy cancer cells, or disrupting important biological pathways.

Understanding cancer biology at a molecular level is typically the first step in discovering anticancer drugs by locating specific molecular targets or pathways that are dysregulated in cancer cells. Genomic and proteomic advances, among other omics tools, have illuminated the genetic and molecular changes linked to various cancers in ways never before seen. Finding driver mutations, oncogenes, and tumor suppressor genes helps in rationally designing drugs that can target cancer cells' weaknesses while avoiding healthy tissues.

**IMPACT OF ANTICANCER-BASED COMPOUNDS**

The therapy landscape for cancer has been revolutionized by anticancer-based chemicals, which offer hope in the never-ending fight against this complicated and frequently fatal disease cluster. With their wide range of chemical structures and therapeutic modalities, these chemicals have changed the face of oncology by opening up new therapy options, enhancing patient outcomes, and altering both molecular and clinical approaches to cancer.

The capacity of anticancer drugs to zero in on particular molecular weaknesses in cancer cells is a driving force behind this influence. Therapy based on the specific genetic and molecular traits of individual cancers has replaced more conventional, generally cytotoxic methods as the new standard in precision medicine. More effective and selective interventions have been made possible by the development of targeted therapies, which were made possible by the identification of actionable mutations, oncogenes, and signaling pathways. This individualized strategy has shown to be highly effective in malignancies where unique genetic abnormalities cause carcinogenesis, such as melanoma with BRAF mutations or non-small cell lung cancer with EGFR mutations.

The effectiveness of targeted therapy is best demonstrated by small molecule inhibitors, a significant class of anticancer drugs. The therapy of chronic myeloid leukemia (CML) has been transformed by drugs like imatinib, which suppress the activation of tyrosine kinases like BCR-ABL. Treatment efficacy and patient survival are both dramatically enhanced by these chemicals because they zero in on the abnormal signaling pathways that are associated with cancer. As a model for the creation of tyrosine kinase inhibitors for use in the treatment of many types of cancer, imatinib's influence goes well beyond CML.

Another revolutionary influence of anticancer-based chemicals is the development of immunotherapy. Recent advances in cancer treatment have made possible the use of chimeric antigen receptor (CAR) T-cell treatments, immune checkpoint inhibitors, and monoclonal antibodies to train the immune system to seek out and destroy cancer cells. The immunological checkpoints that cancer cells use to avoid detection can be disrupted by checkpoint inhibitors like nivolumab and pembrolizumab. These chemicals have shown remarkable efficacy in treating many diseases, including melanoma and lung cancer, with long-lasting effects and higher survival rates.

Immunotherapy has had a significant influence on hematologic malignancies as well as solid tumors. Tisagenlecleucel and axicabtagene ciloleucel are examples of CAR T-cell therapies that use the patient's own T cells to target cancer cells with specific antigens. This groundbreaking method has demonstrated the promise of immunotherapy for a variety of hematologic cancers, with impressive results in patients with certain forms of leukemia and lymphoma.

Another way that treatment tactics have been enhanced is through combination therapy, which use many anticancer substances or modalities to their synergistic advantage. Optimizing efficacy while limiting toxicity is the goal of chemotherapy combinations with targeted treatments or immunotherapies. Patients with breast cancer tested positive for HER2 have shown markedly improved outcomes when chemotherapy and trastuzumab, a HER2-targeted monoclonal antibody, are administered together. It is clear that certain combinations have an effect on response rates, disease progression delay, and overall survival.

Compounds derived from anticancer research have had a significant influence in both the adjuvant and neoadjuvant contexts, not only on patients with advanced or metastatic cancer.

After main therapy (radiation or surgery), patients may have adjuvant therapies to eradicate any remaining cancer cells and lessen the likelihood of recurrence. Prior to initial therapy, neoadjuvant medicines are used to reduce tumor size, make surgical resection easier, and boost results. To address minimal residual disease and increase the chance of long-term disease control, targeted medicines and immunotherapies are used strategically in these conditions.

Adjuvant treatments like tamoxifen and aromatase inhibitors have had a tremendous effect on breast cancer, greatly lowering the recurrence rate and increasing survival rates in hormone receptor-positive subtypes. Similarly, anti-HER2 medicines in HER2-positive breast cancer and other targeted neoadjuvant treatments have shown remarkable efficacy in reducing tumor stage and increasing the chance of breast-conserving surgery.

Palliative care is another area where anticancer drugs have an effect, significantly enhancing the quality of life of people whose cancers have progressed or are incurable. Palliative care focuses on alleviating suffering by managing pain and other symptoms and reducing the likelihood of adverse consequences caused by treatment. Cancer and its treatments can be physically and emotionally taxing, but there are anticancer substances that can ease this load. These include analgesics, antiemetics, and supportive therapies. Further improving the overall impact on patients' lives, targeted treatments and immunotherapies in the palliative environment have the potential to lengthen survival and enhance symptom control.

**DGATI-INHIBITING AND ANTICANCER-BASED COMPOUNDS**

There are two interesting and potentially life-changing fields of study: drugs that inhibit DGAT1 and chemicals that target cancer. There is hope for improving cancer treatments and tackling metabolic diseases at the crossroads of these disciplines. Both paths highlight the ever-changing nature of scientific inquiry in the pursuit of innovative and effective treatments by involving complex procedures of chemical synthesis, bio-assessment, and possible therapeutic applications.

Essential for lipid metabolism and triglyceride synthesis in particular is the enzyme DGAT1, which stands for diacylglycerol O-acyltransferase 1. Metabolic diseases including obesity and insulin resistance can be exacerbated by dysregulation of lipid metabolism, even though

triglycerides are vital for the body's energy storage and transportation. As a possible treatment option for metabolic diseases, DGAT1-inhibiting chemicals aim to regulate lipid levels by targeting and obstructing the enzyme's action.

Integrating concepts from medicinal chemistry, structural biology, and biochemistry, the synthesis of drugs blocking DGAT1 requires a multidisciplinary approach. Achieving strong and selective inhibition of DGAT1 is the goal of medicinal chemists as they develop and optimize pharmaceutical compounds. To improve the selectivity and effectiveness of compounds, structure-activity relationship (SAR) studies direct structural modifications. In order to find the most effective binding sites and interactions for DGAT1 inhibition, rational drug design takes advantage of knowledge about the enzyme's three-dimensional structure.

A crucial step in evaluating the therapeutic potential of drugs that inhibit DGAT1 is conducting bio-assessments. Researchers can evaluate these substances' effects on cellular lipid metabolism processes using in vitro investigations employing cell culture models. The effectiveness and selectivity of DGAT1 inhibition can be quantitatively determined using assays that measure triglyceride levels, lipid droplet formation, and other indicators. Research in this area also looks at side effects and how well it works against other enzymes that are involved in lipid production.

Evaluating the safety and effectiveness of DGAT1 inhibitors in a physiological setting relies heavily on in vivo studies, which are frequently carried out using animal models. To determine how inhibitors affect lipid profiles, body weight, and glucose homeostasis, researchers frequently use rodents like rats and mice. The effects of DGAT1 inhibition on lipid distribution and accumulation can be better understood by histological examinations of various tissues, such as adipose tissue and liver. To fully grasp the metabolic effects of DGAT1 inhibitors, it is necessary to do metabolic evaluations including glucose tolerance testing.

One aspect of DGAT1 inhibitor bio-assessment is investigating their possible therapeutic uses in the treatment of metabolic diseases. Abnormal lipid metabolism is frequently linked to obesity, which is defined by an excess of adipose tissue. In preclinical models of obesity, DGAT1 inhibitors are studied for their potential to decrease body weight, adiposity, and enhance metabolic parameters. Another area that is being studied is the possibility that

inhibiting DGAT1 could help reduce insulin resistance, which is a characteristic of type 2 diabetes.

An additional aspect of bio-assessment is cardiovascular health, since high triglyceride levels increase the likelihood of cardiovascular illnesses. In preclinical models, studies assess the effects of DGAT1 inhibitors on lipid profiles, the development of atherosclerosis, and cardiovascular events. These evaluations provide important information that may help clarify the possible cardiometabolic advantages of DGAT1 inhibition.

A vital part of bio-evaluation is safety assessment, which makes sure that DGAT1 inhibitors don't have any side effects that could reduce their effectiveness as a treatment. Research on the effects of DGAT1 inhibitors on different bodily systems is carried out in animal models as part of toxicology investigations. Research like this looks at the possibility of cytotoxicity, organ toxicity, and other side effects from the inhibitors over time. It is also important to determine the metabolic destiny of DGAT1 inhibitors, which includes their absorption, distribution, metabolism, and excretion, as well as to evaluate the possibility for drug-drug interactions, as part of bio-assessment.

The goal of translational research is to bring DGAT1 inhibitors from the realm of animal studies to the realm of human medicines by bridging the gap between the two. An essential part of bio-assessment is conducting clinical trials on human patients to determine the safety, effectiveness, and tolerability of DGAT1 inhibitors. The primary goals of DGAT1 inhibitors in phase I studies in healthy volunteers are to establish the drug's safety, pharmacokinetics, and optimal dose. Potential therapeutic effects of DGAT1 inhibition in a clinical environment can be better understood through phase II trials, which expand the examination to patients with specific metabolic diseases.

Phase III clinical trials evaluate the effectiveness of DGAT1 inhibitors in contrast to placebos or standard treatments with bigger patient populations. The therapeutic effects seen in previous stages of clinical development and preclinical investigations are what these trials are trying to validate. In order to determine how DGAT1 inhibitors affect the specified metabolic pathways, bio-assessment in clinical trials involves keeping tabs on pertinent biomarkers, lipid profiles, and metabolic parameters. In addition, bio-assessment plays a crucial role in

clinical development by conducting safety assessments and monitoring for possible adverse effects.

In the actual world, bio-assessment includes post-marketing surveillance as a continuing component. It is critical to continuously evaluate the safety and efficacy of DGAT1 inhibitors once they obtain regulatory approval and enter the market. The long-term effects of DGAT1 inhibitors on metabolic health and any unusual side effects that might not have been noticeable during development can be better understood with the use of pharmacovigilance and studies conducted over longer periods of time. The continued safety and effectiveness of DGAT1 inhibitors in varied patient populations is ensured through bio-assessment in the post-marketing phase.

Potential uses of DGAT1 inhibitors in fields like oncology show that their effects are far-reaching and not limited to metabolic diseases. A promising approach to cancer treatment is the targeting of lipid synthesis enzymes, such as DGAT1, due to the important role that lipid metabolism plays in the proliferation and survival of cancer cells. Investigating how blocking DGAT1 influences tumor development, metastasis, and the tumor microenvironment is the primary goal of cancer bio-assessment research. Important factors in the bio-assessment of DGAT1 inhibitors' potential oncological uses include their safety and tolerability in cancer patients.

A thorough and methodical approach is necessary due to the complex bio-assessment in relation to DGAT1 inhibition. There is an ongoing cycle of improvement along the path from bench to bedside, beginning with the synthesis of new chemicals and ending with the thorough assessment of their effects on cellular and physiological processes. We can only progress in our knowledge of lipid metabolism and in the development of tailored treatments for better human health if bio-assessment efforts are robust, and this includes the potential of DGAT1 inhibitors as therapeutic agents for metabolic disorders and beyond.

Cancer is a complicated and diverse set of disorders defined by uncontrolled cell development; concurrently, the domain of anticancer-based chemicals is an active and varied area devoted to fighting cancer. From conventional chemotherapy to targeted treatments and immunotherapies, anticancer-based chemicals have a far-reaching influence on cancer treatment.

Chemicals that target and inhibit cancer cell survival and proliferation are synthesized throughout the process of anticancer drug development. To create molecules with the best possible drug-like features, such as pharmacokinetics, selectivity, and potency, medicinal chemists are indispensable. The goal of structure-activity relationship (SAR) investigations is to improve the inhibitory action of drugs against cancer-specific targets by modifying their chemical structures. By delving into the three-dimensional structure of target proteins, rational drug design methodologies can pinpoint important binding sites and interactions that can be used to construct inhibitors.

An extensive evaluation of the safety, effectiveness, and mechanisms of action of anticancer-based substances is the goal of bio-assessment. To begin evaluating the chemicals' cytotoxicity and antiproliferative effects on cancer cells, in vitro investigations are performed utilizing cell lines or three-dimensional tissue cultures. The effects of the chemicals on cell death, cell cycle progression, and DNA repair pathways are also investigated in these investigations. To find the therapeutic window, or the dosage range where the drug efficiently kills cancer cells while causing the least amount of damage to healthy tissues, bio-assessment of cytotoxicity is essential.

One of the most important parts of bio-assessment is in vivo studies, which use preclinical animal models to learn about the systemic effects and possible toxicity of anticancer drugs in real people. The pharmacokinetics, distribution, metabolism, and excretion of substances are typically studied in rodents, most frequently rats or mice. Researchers can test agents for anticancer effects on tumor development and metastasis using tumor xenograft models, which include implanting human cancer cells into animals. The in vivo effectiveness, safety, and side effect profiles of the drugs have been greatly improved by these investigations.

## CONCLUSION

Using microwave irradiation, we created a new process for synthesising 3, 5-disubstituted 1,2,4-oxadiazoles from various aromatic or alicyclic amidoximes, some of which were substituted or unsubstituted, and benzoyl cyanides that were already on the market. An essential step in this other approach is the cyclization of O-carboxyphenyl amidoxime to oxadiazole analogs via heating. These reactions produced respectable yields using straightforward synthetic techniques that did not involve laborious purification processes.

This study also investigated the possibility of using this new approach to synthesize 1,2,4-oxadiazols from amidoximes and benzoyl cyanide. Synthesis and bio-assessment of anticancer-based chemicals and compounds that inhibit DGAT1 are examples of cutting-edge, multidisciplinary areas in biomedical research. There is an ongoing and cooperative process involved in both the design and production of chemicals and the thorough assessment of their safety, effectiveness, and action mechanisms. The field of drug development is being influenced by the growing body of knowledge about metabolic disorders, lipid metabolism, and cancer biology. This newfound knowledge should lead to better therapies, better patient outcomes, and a better understanding of how the human body works as a whole.

**REFERENCES**

1. Belskaya, N.P., A.V. Koksharov, S.G. Lesogorova, P.A. Slepukhin and V.A. Bakulev (2011). Reactions of 2-arylhydrazonoacetamidoximes with orthoesters, Russ. Chem. Bull. Int. Ed., Vol. 60, pp. 889–895.

2. Bhanot, S., K. Dobie, X-X Yu and B. Monia (2005). Oligonucleotide sequences for use in controlling diacylglycerol acyltransferase 2 a treatment and prevention of diabetes, liver and cardiovascular disorders; antisense agents, US20050272680A1.

3. Bickerdike, M.J. (2003). 5-HT2C receptor agonists as potential drugs for the treatment of obesity, Curr. Top. Med. Chem., Vol. 3, pp. 885–897.

4. Birch, A.M., S. Birtles, L.K. Buckett, P.D. Kemmitt, G.J. Smith, T.J.D. Smith, A.V. Turnbull and S.J.Y. Wang (2009). Discovery of a Potent, Selective, and Orally Efficacious Pyrimidinooxazinyl Bicyclooctaneacetic Acid Diacylglycerol Acyltransferase-1 Inhibitor, J. Med. Chem., Vol. 52, pp. 1558–1568.

5. Blum, C.A., X. Zheng and S.D. Lombaert (2004). Design, synthesis, and biological evaluation of substituted 2-cyclohexyl-4-phenyl-1H-imidazoles: potent and selective neuropeptide Y Y5-receptor antagonists, J. Med. Chem., Vol. 47, pp. 2318–2325.

6. Bolton, R.E., S.J. Coote, H. Finch, A. Lowdon, N. Pegg and M.V. Vinader (1995). 3-Substituted-1,2,4-Oxadiazolin-5-one; A Useful Amidine Precursor and Protecting Group, Tetrahedron Lett., Vol. 36, pp. 4471–4474.

7. Bora, R.O. and M.J. Farooqui (2007). Synthesis of substituted 1,2,4-oxadiazoles from substituted acid chlorides and amidoximes under mild conditions, J. Heterocycl. Chem., Vol. 44, pp. 645–649.

8. Borg, S., G. Estenne-Bouhtou, K. Luthman, I. Csöregh, W. Hesselink and U. Hacksell (1995). Synthesis of 1,2,4-Oxadiazole-, 1,3,4-Oxadiazole-, and 1,2,4-Triazole-Derived Dipeptidomimetics, J. Org. Chem., Vol. 60, pp. 3112–3120.

9. Borg, S., R.C. Vollinga, M. Labarre, K. Payza, L. Terenius and K. Luthman (1999). Design, Synthesis, and Evaluation of Phe-Gly Mimetics: Heterocyclic Building Blocks for Pseudopeptides, J. Med. Chem., Vol. 42, pp. 4331–4342.

10. Brayand, F. and B. Moller (2006). Predicting the future burden of cancer. Nat. Rev. Cancer, Vol. 6, pp. 63–74.

11. Cases, S., P. Zhou, J.M. Shillingford, B.S. Wiseman, J.D. Fish, C.S. Angle, L. Hennighausen, Z. Werb and R.V. Farese, Jr. (2004). Development of the mammary gland requires DGAT1 expression in stromal and epithelial tissues, Development, Vol. 131, pp. 3047–3055.

12. Cases, S., S.J. Smith, Y.W. Zheng, H.M. Myers, S.R. Lear, E. Sande, S. Novak, C. Collins, C.B. Welch, A.J. Lusis, S.K. Erickson and R.V. Farese Jr. (1998). Identification of a gene encoding an acyl CoA: diacylglycerol acyltransferase, a key enzyme in triacylglycerol synthesis, Proc. Natl. Acad. Sci. USA., Vol. 95, pp. 13018– 13023.

13. Cawley, J. and C. Meyerhoefer (2012). The medical care costs of obesity: an instrumental variables approach, J. Health Econ., Vol. 31, pp. 219–230.

14. Chen, H.C., S.J. Smith, B. Tow, P.M. Elias and R.V. Farese, Jr. (2002). Leptin modulates the effects of acyl CoA:diacylglycerol acyltransferase deficiency on murine fur and sebaceous glands, J. Clin. Invest., Vol. 109, pp. 175–181.

15. Chen, H.C., Z. Ladha and R.V. Farese, Jr. (2002). Deficiency of acyl coenzyme a:diacylglycerol acyltransferase 1 increases leptin sensitivity in murine obesity models, Endocrinology, Vol. 143, pp. 2893–2898.

International Journal for Innovative Engineering and Management Research
PEER REVIEWED OPEN ACCESS INTERNATIONAL JOURNAL
www.ijiemr.org